Cardiac Effects of Ergogenic Aides and Supplements

  • Holly J. Benjamin
  • Joseph A. Congeni


Great concern exists that athletes who regularly exercise are using dietary supplements and other purported ergogenic aids as a means for enhancing athletic performance and altering body composition.


Infective Endocarditis Anabolic Steroid Energy Drink Athletic Performance Androgenic Anabolic Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Herbal treatments: the promises and pitfalls. Consum Rep. 1999;64:44–48.Google Scholar
  2. 2.
    Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med. 2001;11:51–56.PubMedCrossRefGoogle Scholar
  3. 3.
  4. 4.
    Deligiannis A, Bjöornstad H, Carre F, et al. ESC Study Group of Sports Cardiology. ESC Study Group of Sports Cardiology Position Paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13:687–694.PubMedCrossRefGoogle Scholar
  5. 5.
    Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252–1262.PubMedGoogle Scholar
  6. 6.
    Kerr JM, Congeni JA. Anabolic-androgenic steroids: use and abuse in pediatric patients. Pediatr Clin N Am. 2007;54:771–785.CrossRefGoogle Scholar
  7. 7.
    Sadler MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37:224–230.CrossRefGoogle Scholar
  8. 8.
    Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp. 1989;4:254–271.PubMedCrossRefGoogle Scholar
  9. 9.
    Glazer G. Arthogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med. 1991;151:1925–1933.PubMedCrossRefGoogle Scholar
  10. 10.
    Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–554.PubMedCrossRefGoogle Scholar
  11. 11.
    National Institute on Drug Abuse Research Report – Steroid Abuse and Addiction. National Institutes of Health Education Publication No. 00–3721. Bethesda (MD): National Institutes of Health; 2000.Google Scholar
  12. 12.
    Hartgens F, Reitjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoprotiesn and lipoproteins (a). Br J Sports Med. 2004;38:253–259.PubMedCrossRefGoogle Scholar
  13. 13.
    Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc. 1992;24:633–637.PubMedGoogle Scholar
  15. 15.
    McKillop G, Todd IC, Ballantine D. Increased left ventricular mass in a bodybuilder using anabolic steroids. Br J Sports Med. 1986;20:151–152.PubMedCrossRefGoogle Scholar
  16. 16.
    Urhausen A, Holpes R, Kindermann W. One and two-dimensional echocardiography in body builders using anabolic steroids. Eur J Appl Physiol. 1989;58:633–640.CrossRefGoogle Scholar
  17. 17.
    Sullivan M, Martinez C, Gallagher J. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851–857.PubMedCrossRefGoogle Scholar
  18. 18.
    Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004;90(5):496–501.PubMedCrossRefGoogle Scholar
  19. 19.
    Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25(5):756–761.PubMedCrossRefGoogle Scholar
  20. 20.
    Cocaine and opiates found in Caminiti’s body. November 1, 2004, Scholar
  21. 21.
    Corrigan B. DHEA and sport. Clin J Sport Med. 2002;12:236–241.PubMedCrossRefGoogle Scholar
  22. 22.
    Holden C. Interest grows in anti-aging drug. Science. 1995;269:33.Google Scholar
  23. 23.
    Di Pasquale MG. Dehydroepitestosterone (DHEA). Drugs Sport. 1994;2:2–3.Google Scholar
  24. 24.
    Issajenko A. Running Risks. Macmillan, Canada. 1990:146.Google Scholar
  25. 25.
    Deyssig R. Frisch H. Blum WF, et al. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol. 1993;128:313–318.PubMedGoogle Scholar
  26. 26.
    Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Bailliere’s Clin Endocrinol Metab. 2000;14:99–109.Google Scholar
  27. 27.
    Dean H. Does exogenous growth hormone improve athletic performance? Clin J Sport Med. 2002;12:250–253.PubMedCrossRefGoogle Scholar
  28. 28.
    Rogol A. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr. 2000;12:382–387.PubMedCrossRefGoogle Scholar
  29. 29.
    Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol. 2001;54:137–154.CrossRefGoogle Scholar
  30. 30.
    Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sport Exerc. 1999;31:639–645.CrossRefGoogle Scholar
  31. 31.
    Vergouwen PC, Collee T, Marx JJ. Haematocrit in elite athletes. Int J Sports Med. 1999;20:538–541.PubMedCrossRefGoogle Scholar
  32. 32.
    Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med. 2004;151:847–849.CrossRefGoogle Scholar
  33. 33.
    World Anti-Doping Agency. The World Anti-Doping Code – The 2009 prohibited list, International Standard. Lausanne: WADA; 2008. Web site
  34. 34.
    George A. Central nervous system stimulants. Bailliere’s Clin Endocrinol Metab. 2000;14:79–88.Google Scholar
  35. 35.
    Cregler L. Substance abuse in sports: The impact of cocaine, alcohol, steroids, and other drugs on the heart. In: Williams RA, ed. The Athlete and Heart Disease: Diagnosis, Evaluation and Management. Philadelphia: Lippincott, Williams and Wilkins; 1999:131–153.Google Scholar
  36. 36.
    Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol. 1995;25:113–132.PubMedCrossRefGoogle Scholar
  37. 37.
    Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–1545.PubMedCrossRefGoogle Scholar
  38. 38.
    Williams AD, Cribb PJ, Cooke MB, et al. The effect of ephedra and caffeine on maximal strength and power in resistance-trained athletes. J Strength Cond Res. 2008;22:464–470.PubMedCrossRefGoogle Scholar
  39. 39.
    Malek MH, Housh TJ, Coburn JW, et al. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. J Strength Cond Res.2006;20(4):751–755.PubMedGoogle Scholar
  40. 40.
    Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med. 2002;12:245–249.PubMedCrossRefGoogle Scholar
  41. 41.
    Clauson KA, Shields KM, McQueen CE, et al. Safety issues associated with commercially available energy drinks. J Am Pharm Assoc. 2008;48(3):e55–e63.CrossRefGoogle Scholar
  42. 42.
    Graham TE, Spriet LL. Caffeine and exercise performance. Sport Sci Exerc. 1996;9:1.Google Scholar
  43. 43.
    Australia New Zealand Food Authority. Report of the expert group on the safety aspects of dietary caffeine ANZFA, Canberra. 2000.Google Scholar
  44. 44.
  45. 45.
    Ellison RC, Singer MR, Moore LL. Current caffeine intake of young children; amount and sources. J Am Diet Assoc. 1995;95:802–803.PubMedCrossRefGoogle Scholar
  46. 46.
    Morgan KJ, Stults VJ, Zabik ME. Amount and dietary sources of caffeine and saccharin intake by individuals 5–18 years. Regul Toxiol Pharmacol. 1982;2:296–307.CrossRefGoogle Scholar
  47. 47.
    Nawrot P, Jorden S, Eastwood J, Rostein J, Hugenholtz A, Feeley M. Effects of caffeine on human health Food Addit Contam 2003;20:1–30.Google Scholar
  48. 48.
    Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2003;103:1326–1331.CrossRefGoogle Scholar
  49. 49.
    Santa Maria A, Lopez A, Diaz M, et al. Evaluation of toxicity of guarana with invitro bioassays. Ecotoxicol Environ Saf. 1998;39:164–167.PubMedCrossRefGoogle Scholar

Suggested Web sites

  1. American College of Cardiology –
  2. American College of Sports Medicine –
  3. National Collegiate Athletic Association –
  4. United States Anti-Doping Agency –
  5. World Anti-Doping Agency –

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Section of Academic Pediatrics, Section of Orthopedic Surgery and Rehabilitation Medicine, Director of Primary Care Sports MedicineThe University of ChicagoChicagoUSA

Personalised recommendations